Liraglutide, a GLP-1 receptor agonist, reduces HbA1c by multiple mechanisms. Which mechanism is glucose-INDEPENDENT and does not risk hypoglycemia?

• A Stimulation of insulin secretion from pancreatic beta cells
• B Suppression of glucagon secretion from alpha cells
• C Slowing of gastric emptying, reducing postprandial glucose absorption
• D Promotion of central satiety via GLP-1 receptors in the hypothalamus ✓

Explanation

GLP-1 receptor agonists lower HbA1c through glucose-dependent insulin release, glucose-dependent glucagon suppression, slowed gastric emptying, and central appetite suppression. The central satiety effect (via GLP-1 receptors in the hypothalamus and brainstem) is entirely glucose-independent — it reduces caloric intake regardless of blood glucose level. This is why GLP-1 agonists do not cause hypoglycemia when used as monotherapy; insulin release and glucagon suppression are tightly glucose-dependent and diminish when glucose normalizes.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.